FSUE Endopharm has launched the industrial production of the Mesna chemoprotector for patients with cancer undergoing chemotherapy, the company’s press service reported. A month earlier, the Ministry of Health issued a registration certificate for the production of the drug in the form of a 100 mg/ml intravenous solution.
“The localization of “Mesna” production at the Moscow Endocrinology Plant manufacturing site in accordance with GMP standards will meet the healthcare system’s need for the drug, which has been included in the list of essential medicines,” the press service said, noting that the release of the first batch into civilian circulation is scheduled for November.
Mesna is used as part of combination chemotherapy for cancer, including ovarian, breast, lung, head and neck carcinomas, bone and soft tissue sarcomas, lymphomas, and leukemias, in children and adults. The drug reduces the risk of hemorrhagic cystitis, a specific lesion of the bladder caused by cytotoxic drugs.
It should be noted that, according to the State Register of Medicines, four other companies, in addition to Endopharm, sell INN mesna drugs in Russia: Atoll, Veropharm, LANCE-Pharm, and Baxter Oncology GmbH.
Mesna is the third drug in the Endopharma range intended for those undergoing chemotherapy, the company said. Since 2008, the plant has been producing Metoclopramide solution for intravenous and intramuscular administration, and production of Phosaprepitant-ET lyophilizate will begin in the second half of 2026. These medications are used to prevent nausea and vomiting during and after chemotherapy.
